Targeting endothelial cell Gch1 and BH4 biosynthesis may provide a novel therapeutic target for the prevention and treatment of pregnancy-related hypertension, preeclampsia, and fetal growth retardation. The gene discussed is GCH1; the disease is preeclampsia.